

Daniel B Costa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2724878/daniel-b-costa-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

17,397
citations

46
h-index

131
g-index

186
ext. papers

19,989
ext. citations

6.3
avg, IF

6.26
L-index

#	Paper	IF	Citations
169	Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 1769-1770	59.2	0
168	Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for -Amplified Tumors With -D1228X or -Y1230X Mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 1001-1007	1.4	14
167	Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. <i>JTO Clinical and Research Reports</i> , 2021 , 2,	1.4	6
166	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021 , 22, e379-e389	4.9	4
165	The rapidly evolving landscape of biomarker testing in non-small cell lung cancer. <i>Cancer Cytopathology</i> , 2021 , 129, 179-181	3.9	5
164	PI-RADS Version 2.1: A Critical Review, From the Special Series on Radiology Reporting and Data Systems. <i>American Journal of Roentgenology</i> , 2021 , 216, 20-32	5.4	16
163	Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. <i>Oncologist</i> , 2021 , 26, 281-287	5.7	6
162	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021 , 5, 325-332	3.6	1
161	Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. <i>JAMA Network Open</i> , 2021 , 4, e2037120	10.4	16
160	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021 , 11, 1688-1699	24.4	57
159	Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. <i>Cancer Medicine</i> , 2021 , 10, 1545-1549	4.8	2
158	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2020 , 1,	1.4	9
157	Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized? 2020 , 8,		11
156	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020 , 145, 181-185	5.9	18
155	Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9507-9507	2.2	9
154	Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9533-9533	2.2	1
153	Time to COVID-19 RT-PCR clearance among patients with cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 49-49	2.2	0

152	Comparison of outcomes with pembrolizumab monotherapy (P) versus combination with chemotherapy (P+C) in advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21579-e21579	2.2	
151	Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by -D1228 and -Y1230 Mutations in -Mutated -Amplified Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100071	1.4	6
150	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020 , 1, 100074	1.4	4
149	Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. <i>Clinical Lung Cancer</i> , 2020 , 21, e6-e9	4.9	2
148	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. <i>Frontiers in Oncology</i> , 2020 , 10, 1193	5.3	5
147	Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?. <i>Precision Cancer Medicine</i> , 2020 , 3,	1	8
146	Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib. <i>JACC: CardioOncology</i> , 2020 , 2, 119-122	3.8	2
145	TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Mutations. <i>Molecular Cancer Research</i> , 2019 , 17, 2233-2243	6.6	24
144	Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naïve Programmed Death Ligand 1-Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e34-e36	8.9	
143	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019 , 133, 96-102	5.9	53
142	miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. <i>Nature Metabolism</i> , 2019 , 1, 460-474	14.6	32
141	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 97-104	2.2	83
140	Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e1-e3	8.9	4
139	EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1995-2002	8.9	34
138	Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8507-8507	2.2	2
137	Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9007-9007	2.2	43
136	EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20593-e20593	2.2	1
135	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20617-e20617	2.2	

134	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. <i>Journal of the American Society of Cytopathology</i> , 2018 , 7, 133-141	2.4	42
133	Tumor biomarker testing in non-small-cell lung cancer: A decade of change. <i>Lung Cancer</i> , 2018 , 116, 90-95	5.9	38
132	Updated Correlation of 22C3-PD-L1 80% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e81-e83	8.9	
131	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1037-1042	8.9	58
130	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. <i>Cancer Treatment and Research Communications</i> , 2018 , 15, 17-20	2	7
129	Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. <i>JAMA Oncology</i> , 2018 , 4, 1527-1534	13.4	342
128	Amplification of Wild-type Imparts Resistance to Crizotinib in Exon 14 Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5963-5976	12.9	42
127	Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. <i>Clinical Lung Cancer</i> , 2018 , 19, e589-e590	4.9	9
126	First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9015-9015	2.2	18
125	Targeting rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. <i>Translational Cancer Research</i> , 2018 , 7, S779-S786	0.3	32
124	AuthorsLResponse. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e237	8.9	
123	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. <i>Annals of Oncology</i> , 2018 , 29, 2092-2097	10.3	36
122	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. <i>Clinical Cancer Research</i> , 2018 , 24, 6548-6555	12.9	31
121	Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. <i>Lung Cancer</i> , 2017 , 106, 17-21	5.9	111
120	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 80% Expression in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 878-883	8.9	94
119	MA04.02 Neratinib  Temezirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S358-S359	8.9	29
118	Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1288-1298	8.9	44
117	Ascending role of next-generation ALK inhibitors. <i>Lancet Oncology</i> , 2017 , 18, 837-839	21.7	4

116	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1183-1209	8.9	29
115	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e175-e177	8.9	10
114	Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. <i>Clinical Lung Cancer</i> , 2017 , 18, e349-e356	4.9	23
113	P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1072-S1073	8.9	3
112	P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1302-S1303	8.9	9
111	Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e35-e36	8.9	2
110	Size Measurement and T-staging of Lung Adenocarcinomas Manifesting as Solid Nodules \geq 8 mm on CT: Radiology-Pathology Correlation. <i>Academic Radiology</i> , 2017 , 24, 851-859	4.3	19
109	Morphologic characteristics of pulmonary adenocarcinomas manifesting as pure ground-glass nodules on CT. <i>Journal of Thoracic Disease</i> , 2017 , 9, E1148-E1150	2.6	1
108	De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma. <i>Lung Cancer</i> , 2017 , 114, 108-110	5.9	3
107	"Rounding" the Size of Pulmonary Nodules: Impact of Rounding Methods on Nodule Management, as Defined by the 2017 Fleischner Society Guidelines. <i>Academic Radiology</i> , 2017 , 24, 1422-1427	4.3	10
106	Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?. <i>Cell Cycle</i> , 2017 , 16, 19-20.	4.7	3
105	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. <i>Translational Cancer Research</i> , 2017 , 6, S151-S157	0.3	1
104	De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. <i>Lung Cancer</i> , 2016 , 99, 17-22	5.9	13
103	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 6010-6020	12.9	84
102	Thymic carcinoma with brain metastases: A rare presentation of a rare malignancy. <i>Cancer Treatment Communications</i> , 2016 , 7, 21-22		
101	EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. <i>Clinical Lung Cancer</i> , 2016 , 17, 483-492	4.9	41
100	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016 , 10, 113-29.	4.9	97
99	Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 918-23	8.9	25

98	ALK inhibitors: plateauing systemic and intracranial activity?. <i>Lancet Oncology, The</i> , 2016 , 17, 404-406	21.7	6
97	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016 , 7, 10501	17.4	846
96	Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e81-2 ^{8.9}	8.9	16
95	Endoluminal contrast for abdomen and pelvis magnetic resonance imaging. <i>Abdominal Radiology</i> , 2016 , 41, 1378-98	3	3
94	The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 383-90	3.5	46
93	Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016 , 24, 187-204	1.6	10
92	Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth. <i>Oncotarget</i> , 2016 , 7, 23919-32	3.3	28
91	Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. <i>Translational Lung Cancer Research</i> , 2016 , 5, 331-7	4.4	39
90	Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial. <i>JAMA Oncology</i> , 2016 , 2, 1240-2	13.4	12
89	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2858-65 ^{2.2}	2.2	171
88	Comprehensive Genomic Profiling Differentiates Metachronous Primary Small-Cell Lung Cancer From Late Recurrence. <i>Clinical Lung Cancer</i> , 2016 , 17, e169-e172	4.9	
87	Rapidly fatal advanced -mutated lung cancers and the need for rapid tumor genotyping in clinical practice. <i>Cancer Treatment and Research Communications</i> , 2016 , 9, 41-43	2	4
86	Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. <i>Lung Cancer</i> , 2015 , 88, 108-11	5.9	243
85	Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline. <i>JAAD Case Reports</i> , 2015 , 1, 289-91	1.4	3
84	De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. <i>Lung Cancer</i> , 2015 , 88, 70-3	5.9	21
83	The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. <i>Clinical Lung Cancer</i> , 2015 , 16, 334-339.e1	4.9	21
82	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. <i>Clinical Lung Cancer</i> , 2015 , 16, e105-9	4.9	9
81	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015 , 90, 369-74	5.9	59

80	Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015 , 4, 174-181		22
79	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1670-4	8.9	166
78	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. <i>Nature Communications</i> , 2015 , 6, 6377	17.4	358
77	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1881-8	2.2	454
76	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8015-8015	2.2	10
75	CCAAT/enhancer binding protein β s dispensable for development of lung adenocarcinoma. <i>PLoS ONE</i> , 2015 , 10, e0120647	3.7	2
74	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 38789-803	3.3	104
73	Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. <i>Translational Lung Cancer Research</i> , 2015 , 4, 809-15	4.4	39
72	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015 , 4, 392-403	4.4	16
71	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 84, 39-44	5.9	103
70	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. <i>Lung Cancer</i> , 2014 , 83, 37-43	5.9	68
69	Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1963-71	59.2	1267
68	EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. <i>Targeted Oncology</i> , 2014 , 9, 389-94	5	3
67	Ecaterin contributes to lung tumor development induced by EGFR mutations. <i>Cancer Research</i> , 2014 , 74, 5891-902	10.1	60
66	Management and future directions in non-small cell lung cancer with known activating mutations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e353-65	7.1	62
65	Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 248-53	8.9	11
64	Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer. <i>Translational Lung Cancer Research</i> , 2014 , 3, 373-5	4.4	2
63	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 216ra177	17.5	313

62	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. <i>Annals of Oncology</i> , 2013 , 24, 59-66	10.3	82
61	Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. <i>Lung Cancer</i> , 2013 , 79, 193-7	5.9	32
60	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. <i>Lung Cancer</i> , 2013 , 82, 31-7	5.9	42
59	Safety of cupping during bevacizumab therapy. <i>Journal of Alternative and Complementary Medicine</i> , 2013 , 19, 729-31	2.4	5
58	Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 45-51	8.9	114
57	Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1434-7	8.9	37
56	Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e23-4	8.9	20
55	Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1438-1444	8.9	64
54	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , 2012 , 13, 1011-9	21.7	983
53	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. <i>Lancet Oncology</i> , 2012 , 13, e23-31	21.7	401
52	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012 , 483, 613-7	50.4	361
51	Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. <i>Lung Cancer</i> , 2012 , 77, 31-7	5.9	29
50	Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. <i>Journal of Oncology Practice</i> , 2012 , 8, 57-62	3.1	3
49	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. <i>Clinical Cancer Research</i> , 2012 , 18, 4406-14	12.9	144
48	More than just an oncogene translocation and a kinase inhibitor: Kevin's story. <i>Journal of Clinical Oncology</i> , 2012 , 30, 110-2	2.2	4
47	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1086-90	8.9	124
46	EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e19-20	8.9	21
45	Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 623-5	8.9	10

44	Abstract 23: Sensitivity ofEGFRexon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR 2012 ,		4
43	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1004-12	21.7	73 ²
42	ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1439-40	8.9	18
41	KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 220-2	8.9	
40	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3307-15	2.2	343
39	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. <i>Therapeutic Advances in Medical Oncology</i> , 2011 , 3, 113-25	5.4	77
38	CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, e443-5	2.2	45 ⁰
37	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2010 , 16, 5873-82	12.9	168
36	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
35	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1048-53	8.9	68
34	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010 , 115, 2901-9	2.2	41
33	Serum concentrations of Erlotinib at a dose of 25 mg daily. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 1311-28.9		6
32	Molecular testing in lung cancer: the time is now. <i>Current Oncology Reports</i> , 2010 , 12, 335-48	6.3	18
31	Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population. <i>Jornal Brasileiro De Pneumologia</i> , 2009 , 35, 767-72	1.1	12
30	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4247-53	2.2	146 ²
29	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. <i>Clinical Lung Cancer</i> , 2009 , 10, 281-9	4.9	33 ⁰
28	Gefitinib plus docetaxel in non-small-cell lung cancer. <i>Lancet, The</i> , 2009 , 373, 541; author reply 542	40	
27	Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. <i>Lung Cancer</i> , 2008 , 61, 152-62	5.9	32

26	Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1182-4; author reply 1184-6	2.2	110
25	Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 686	2.2	2
24	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <i>Clinical Cancer Research</i> , 2008 , 14, 7060-7	12.9	135
23	Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. <i>Lung Cancer</i> , 2007 , 56, 97-103	5.9	17
22	To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress. <i>Lung Cancer</i> , 2007 , 57, 251-2	5.9	3
21	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. <i>Lung Cancer</i> , 2007 , 58, 95-103	5.9	140
20	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. <i>PLoS Medicine</i> , 2007 , 4, 1669-79; discussion 1680	11.6	376
19	Erlotinib-associated alopecia in a lung cancer patient. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1136-8	8.9	3
18	A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2611-20	15.9	93
17	A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 3175-3175	2.2	
16	A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2006 , 76, 432-5, 453	3.8	10
15	5-Azacytidine treatment of the patient with ATMDS. <i>European Journal of Haematology</i> , 2006 , 76, 453-453.8		
14	Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. <i>Diabetes Care</i> , 2006 , 29, 1711	14.6	30
13	Recurrent infections in multiple myeloma. <i>Mayo Clinic Proceedings</i> , 2006 , 81, 567-8; author reply 568	6.4	3
12	Three-year survival in metastatic non-small cell lung cancer treated with gefitinib. <i>Lung Cancer</i> , 2006 , 53, 123-4	5.9	5
11	C/EBP alpha mutations in lung cancer. <i>Lung Cancer</i> , 2006 , 53, 253-4	5.9	15
10	Hyperglycemia and biliary tract adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006 , 21, 484-5	4	
9	Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. <i>Nature Genetics</i> , 2006 , 38, 1269-77	36.3	146

8	Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. <i>Journal of the National Medical Association</i> , 2006 , 98, 1183-7	2.3	16
7	A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred. <i>Blood</i> , 2005 , 106, 4367-9	2.2	15
6	Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. <i>Journal of Infection</i> , 2005 , 50, 130-7	18.9	19
5	Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7740-2	2.2	
4	Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature. <i>Endocrine Practice</i> , 2004 , 10, 417-23	3.2	3
3	Pneumococemia as the presenting feature of multiple myeloma. <i>American Journal of Hematology</i> , 2004 , 77, 277-81	7.1	18
2	A Position +5 Intronic Mutation in the β -Spectrin Gene Is Associated with Marked Deficiency of β -Spectrin Production in the First Reported Cases of Hereditary Pyropoikilocytosis.. <i>Blood</i> , 2004 , 104, 576-576	2.2	2
1	Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer		1